Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea : a multicenter retrospective study (KCSG LY20-06)
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jung Sun | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Kang, Myoung Joo | - |
dc.contributor.author | Koh, Sung Ae | - |
dc.contributor.author | Park, Hyunkyung | - |
dc.contributor.author | Nam, Seung-Hyun | - |
dc.contributor.author | Han, Jae Joon | - |
dc.contributor.author | Lee, Gyeong-Won | - |
dc.contributor.author | Yuh, Young Jin | - |
dc.contributor.author | Lee, Hee Jeong | - |
dc.contributor.author | Choi, Jung Hye | - |
dc.date.accessioned | 2023-11-24T04:58:34Z | - |
dc.date.available | 2023-11-24T04:58:34Z | - |
dc.date.created | 2023-07-25 | - |
dc.date.issued | 2023-09 | - |
dc.identifier.issn | 1226-3303 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/192996 | - |
dc.description.abstract | Background/Aims: Little attention is paid to chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) in Korea due to the rarity of the disease. With its rising incidence, we aimed to evaluate recent changes in treatment patterns and survival outcomes of patients with CLL/SLL. Methods: A total of 141 patients diagnosed with CLL/SLL between January 2010 and March 2020 who received systemic therapy were analyzed in this multicenter retrospective study. Results: The median patient age was 66 years at diagnosis, and 68.1% were male. The median interval from diagnosis to initial treatment was 0.9 months (range: 0-77.6 months), and the most common treatment indication was progressive ma row failure (50.4%). Regarding first-line therapy, 46.8% received fludarabine, cyclophosphamide, plus rituximab (FCR), fo lowed by chlorambucil (19.9%), and obinutuzumab plus chlorambucil (GC) (12.1%). The median progression-free survival (PFS) was 49.3 months (95% confidence interval [CI], 32.7-61.4), and median overall survival was not reached (95% CI, 98.4 mo- not reached). Multivariable analysis revealed younger age (<= 65 yr) (hazard ratio [HR], 0.46; p < 0.001) and first-line therapy with FCR (HR, 0.64; p = 0.019) were independently associated with improved PFS.<italic> TP53</italic> aberrations were observed in 7.0% (4/57) of evaluable patients. Following reimbursement, GC became the most common therapy among patients over 65 years and second in the overall population after 2017. Conclusions: Age and reimbursement mainly influenced treatment strategies. Greater effort to apply risk stratifications into practice and clinical trials for novel agents could help improve treatment outcomes in Korean patients. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN ASSOC INTERNAL MEDICINE | - |
dc.title | Treatment pattern of chronic lymphocytic leukemia/small lymphocytic lymphoma in Korea : a multicenter retrospective study (KCSG LY20-06) | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, Jung Hye | - |
dc.identifier.doi | 10.3904/kjim.2022.408 | - |
dc.identifier.scopusid | 2-s2.0-85170295255 | - |
dc.identifier.wosid | 001019047200001 | - |
dc.identifier.bibliographicCitation | KOREAN JOURNAL OF INTERNAL MEDICINE, v.38, no.5, pp.747 - 757 | - |
dc.relation.isPartOf | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.title | KOREAN JOURNAL OF INTERNAL MEDICINE | - |
dc.citation.volume | 38 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 747 | - |
dc.citation.endPage | 757 | - |
dc.type.rims | ART | - |
dc.type.docType | Article; Early Access | - |
dc.identifier.kciid | ART002992283 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | General & Internal Medicine | - |
dc.relation.journalWebOfScienceCategory | Medicine, General & Internal | - |
dc.subject.keywordPlus | OPEN-LABEL | - |
dc.subject.keywordPlus | CLL | - |
dc.subject.keywordPlus | PROGRESSION | - |
dc.subject.keywordAuthor | Leukemia | - |
dc.subject.keywordAuthor | lymphocytic | - |
dc.subject.keywordAuthor | chronic | - |
dc.subject.keywordAuthor | B-cell | - |
dc.subject.keywordAuthor | Insurance | - |
dc.subject.keywordAuthor | health | - |
dc.subject.keywordAuthor | reimbursement | - |
dc.subject.keywordAuthor | Treatment outcome | - |
dc.identifier.url | https://www.kjim.org/journal/view.php?doi=10.3904/kjim.2022.408 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.